Smith & Nephew Spray-On Wound Therapy Misses Leg Ulcer Endpoint
This article was originally published in The Gray Sheet
A phase III study of the firm's live cell spray-on wound therapy (HP802-247) failed, putting the future of the product, acquired by Smith & Nephew in 2012, in question.
You may also be interested in...
As the coronavirus continues to spread, one of the big four global vaccines companies has committed itself to the fight.
Sweden’s mid-sized pharmaceutical company, Swedish Orphan Biovitrum, has expanded into hematology and strengthened its immunology business, growing its top and bottom lines in 2019.